Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The role of neurotropins, predominantly brain-derived neurotropic factor (BDNF), has been implicated in the pathophysiology as well as treatment outcome of schizophrenia. Both human and rodent studies indicate that the beneficial effects of antipsychotic drugs are mediated, at least in part, through BDNF and its receptor, TrkB. This review will discuss the available data on the levels of BDNF and TrkB in subjects with schizophrenia and in animals with and without conventional antipsychotics. The data concerning the impact of the antipsychotic drugs on BDNF/TrkB signaling will also be discussed. More importantly, this review will provide future perspective on BDNF/TrkB signaling as a novel molecular target to correct the pathogenesis and improve the long-term clinical outcome by treatments with conventional and adjunctive drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“PI3K forms 3′-phosphorylated phosphoinositides, which allow the activation of several proteins, including Akt [”
BackgroundOmega-3 fatty acids in health and disease and in growth and development.
Simopoulos, A. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.3.438 · Cited by 2,162
Meta-analysis of regional brain volumes in schizophrenia
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. R., David, A. S., Murray, R. M., & Bullmore, E. T. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.16 · Cited by 1,662
Huang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198
Increasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Dietary (n-3) Fatty Acids and Brain Development1
Innis, S. M. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.4.855 · Cited by 906
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 1×
“The present review will address the role of BDNF signaling via its receptor, TrkB, in the pathophysiology as well as treatment outcome of schizophrenia. Furthermore, this review will provide the basis for BDNF/TrkB signaling as a potential molecular target for novel pharmacotherapy for the restoration of neuropatholog…”
BackgroundLipska, B. K., Jaskiw, G. E., & Weinberger, D. R. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.44 · Cited by 697
Cited by
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390
“Haloperidol and risperidone seem to de- crease BDNF, whereas clozapine and olanzapine may increase BDNF levels in the hippocampus (Pillai, 2008), although other studies indicate that clozapine may have opposite effects in the hippocampus (Durany and Thome, 2004).”
BackgroundResultInfluentialCannabis and psychosis/schizophrenia: human studies
D’Souza, D. C., Sewell, R. A., & Ranganathan, M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0024-2 · Cited by 295
Pillai, A., Kale, A., Joshi, S., Naphade, N., Raju, M. S. V. K., Nasrallah, H., & Mahadik, S. P. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991015 · Cited by 274
Self-citationAntioxidants as potential therapeutics for neuropsychiatric disorders
Pandya, C. D., Howell, K. R., & Pillai, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.017 · Cited by 222
“Evidence from clinical, pre-clinical and epidemiological studies suggest that a benefit of using antioxidant compounds, which enhance neuroprotection, should be considered as adjunctive therapy in these patients (Pillai, 2008).”
Self-citationMatrisciano, F., Tueting, P., Maccari, S., Nicoletti, F., & Guidotti, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.274 · Cited by 110
Metadata
- Authors
- Pillai, A.
- Venue
- Neurosignals
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 16
- Issue
- 2-3
- Pages
- 183-193
- ISSN
- 1424-862X (ISSN-L)
- 1424-8638
- OpenAlex
- W2032163025
- Cited by
- 115
- References
- 16
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. https://app.cochat.ai/papers/10.1159/000111562
- The paper
- Pillai, A. (2008). Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. Neurosignals. https://doi.org/10.1159/000111562
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.